A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
• Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.
• Diagnosed with RP associated with Usher syndrome.
• EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.
• All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
• Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).
• On stable dose of medications associated with other conditions for at least one month.
• Willing to use contraception during study (for anyone of childbearing potential).